This randomized controlled trial evaluated the efficacy of finasteride (1 mg/day) in 137 postmenopausal women aged 41 to 60 with androgenetic alopecia (AGA) over 12 months. Despite its known mechanism of inhibiting type 2 5α-reductase to reduce dihydrotestosterone (DHT), the study found no statistically significant improvement in hair growth, slowing
This systematic review explores the multifaceted causes and treatments of androgenetic alopecia (AGA), emphasizing the importance of early and continuous therapy. It highlights the FDA-approved treatments—topical minoxidil and oral finasteride—while discussing additional therapeutic options targeting androgen activity, inflammation, prostaglandins, and genetic predisposition. The review encourages a personalized, combination-based approach for
This 2007 randomized, placebo-controlled trial published in the European Journal of Dermatology (PMID: 17324826) assessed the safety and efficacy of 1% topical minoxidil in 280 Japanese women with androgenetic alopecia over 24 weeks. The minoxidil group showed a significant increase in non-vellus hair count (mean increase of 8.15 hairs/cm² vs.
This randomized controlled trial investigated the effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone (DHT) levels in men with male pattern baldness. Over 28 days, participants taking 5 mg/day of finasteride experienced a significant reduction in scalp DHT levels (from 6.40 to 3.62 pmol/g) and
This 2004 randomized controlled trial published in the Journal of the American Academy of Dermatology (PMID: 15034503) evaluated the efficacy and safety of 5% and 2% topical minoxidil in 381 women aged 18–49 with female pattern hair loss (FPHL) over 48 weeks. Both concentrations led to significant increases in non-vellus
This randomized controlled trial, published in the International Journal of Dermatology (1992, PMID: 1428436), evaluated the effectiveness and safety of 2% topical minoxidil in 33 women aged 22 to 44 with Ludwig’s grade I or II female androgenetic alopecia. Over a 32-week period, participants using minoxidil saw an average increase
This 2004 randomized controlled trial published in Dermatology (PMID: 15316165) compared the efficacy and safety of oral finasteride (1 mg/day) and 5% topical minoxidil in 65 men with androgenetic alopecia over 12 months. The clinical cure rate—measured by increased hair density—was significantly higher in the finasteride group (80%) compared to
This randomized, double-blind, placebo-controlled trial published in the International Journal of Dermatology (1993, PMID: 8225725) evaluated the safety and effectiveness of 2% topical minoxidil in 256 women aged 18 to 45 with androgenetic alopecia. Over 32 weeks, participants applied 1 mL of solution twice daily. Results showed a statistically significant
This 1994 randomized, double-blind, placebo-controlled trial published in Archives of Dermatology (PMID: 8129407) evaluated the safety and efficacy of 2% topical minoxidil in 308 women with androgenetic alopecia over 32 weeks. Women treated with minoxidil showed a statistically significant increase in non-vellus hair count (23 hairs/cm² vs. 11 in placebo),
This randomized controlled trial, published in the British Journal of Dermatology (2008, PMID: 18363752), evaluated the hormonal impact and treatment response of daily 1 mg finasteride in 270 males aged 14–58 with androgenetic alopecia (AGA), using the Hamilton-Norwood scale III–VI. Over 12 months, younger participants (≤26 years) with higher baseline
